JSPR

Jasper Therapeutics Inc

JSPR, USA

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

https://jaspertx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
JSPR
stock
JSPR

Pharma News: Will Tenaya Therapeutics Inc stock remain a Wall Street favorite - 2025 Market Sentiment & Weekly Return Optimization Plans moha.gov.vn

Read more β†’
JSPR
stock
JSPR

Update Report: How resilient is JSPR stock in market downturns - July 2025 Chart Watch & Safe Entry Point Alerts moha.gov.vn

Read more β†’

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$18.1429

Analyst Picks

Strong Buy

7

Buy

4

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

High

2.60

Low ≀ 1

High β‰₯ 3

Return on Equity (ROE)

-

Very Low

-161.92 %

Low ≀ 5%

High β‰₯ 25%

Return on Assets (ROA)

-

Very Low

-32.60 %

Low ≀ 2%

High β‰₯ 10%

Debt to Equity

-

Very Low

3.97

Low β‰₯ 1

High ≀ 0.3

Investors

* Institutions hold a combined 78.87% of the total shares of Jasper Therapeutics Inc

1.

Soleus Capital Management, L.P.

(9.1945%)

since

2025/06/30

2.

Velan Capital Investment Management LP

(8.8217%)

since

2025/06/30

3.

The Carlyle Group Inc

(6.5598%)

since

2025/06/30

4.

Qiming U.S. Ventures Management, LLC

(5.7155%)

since

2025/06/30

5.

Morgan Stanley - Brokerage Accounts

(4.736%)

since

2025/06/30

6.

T. Rowe Price Investment Management,Inc.

(4.3293%)

since

2025/06/30

7.

Kingdon Capital Management LLC

(4.2127%)

since

2025/06/30

8.

Vanguard Group Inc

(3.8429%)

since

2025/06/30

9.

Integral Health Asset Management, LLC

(3.63%)

since

2025/06/30

10.

Rock Springs Capital Management LP

(3.3542%)

since

2025/06/30

11.

Franklin Resources Inc

(3.2899%)

since

2025/06/30

12.

UBS Group AG

(2.5612%)

since

2025/06/30

13.

Vanguard Total Stock Mkt Idx Inv

(2.5355%)

since

2025/07/31

14.

Citadel Advisors Llc

(2.5253%)

since

2025/06/30

15.

Bank of America Corp

(1.8055%)

since

2025/06/30

16.

Goldman Sachs Group Inc

(1.5369%)

since

2025/06/30

17.

T. Rowe Price U.S. SC Value Eq Tr-D

(1.52%)

since

2025/06/30

18.

BlackRock Inc

(1.3881%)

since

2025/06/30

19.

DWS ESG Biotech LC

(0.9845%)

since

2025/07/31

20.

Deutsche Bank AG

(0.9844%)

since

2025/06/30

21.

Bank of Montreal

(0.9729%)

since

2025/06/30

22.

BMO Capital Markets Corp.

(0.9729%)

since

2025/06/30

23.

Lion Point Capital, LP

(0.9014%)

since

2025/06/30

24.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7774%)

since

2025/07/31

25.

Fidelity Extended Market Index

(0.3811%)

since

2025/07/31

26.

iShares Micro-Cap ETF

(0.1827%)

since

2025/08/31

27.

Extended Equity Market Fund K

(0.1602%)

since

2025/06/30

28.

Fidelity Total Market Index

(0.1273%)

since

2025/07/31

29.

Fidelity Series Total Market Index

(0.1015%)

since

2025/07/31

30.

T. Rowe Price U.S. Equities Tr

(0.1014%)

since

2025/06/30

31.

Spartan Extended Market Index Pool F

(0.0885%)

since

2025/07/31

32.

NT Ext Equity Mkt Idx Fd - L

(0.0795%)

since

2025/06/30

33.

Northern Trust Extended Eq Market Idx

(0.0795%)

since

2025/06/30

34.

Fidelity VIP Disciplined Small Cap Init

(0.0732%)

since

2025/06/30

35.

DFA US Small Cap I

(0.0713%)

since

2025/07/31

36.

Fidelity Nasdaq Composite Index

(0.0594%)

since

2025/07/31

37.

NT Ext Equity Mkt Idx Fd - NL

(0.0592%)

since

2025/06/30

38.

Vanguard Balanced Index Inv

(0.0535%)

since

2025/07/31

39.

AQR Small Cap Momentum Style I

(0.0511%)

since

2025/06/30

40.

Spartan Total Market Index Pool G

(0.0482%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

β€”

EPS Estimate

β€”

Latest Release

Date

2025-09-30

EPS Actual

-1.2524

EPS Estimate

-1.2918

EPS Difference

0.0394

Surprise Percent

3.05%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(1)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.